These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 16924363

  • 1. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
    Tan EL, Looi LM, Sam CK.
    Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
    [Abstract] [Full Text] [Related]

  • 2. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 3. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF, Chan AT, Zee B, Ma B, Chan LY, Johnson PJ, Lo YM.
    Cancer; 2003 Jul 15; 98(2):288-91. PubMed ID: 12872347
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Epstein-Barr virus DNA level in plasma, peripheral blood cell and tumor tissue in nasopharyngeal carcinoma.
    Shao JY, Zhang Y, Li YH, Gao HY, Feng HX, Wu QL, Cui NJ, Cheng G, Hu B, Hu LF, Ernberg I, Zeng YX.
    Anticancer Res; 2004 Jul 15; 24(6):4059-66. PubMed ID: 15736452
    [Abstract] [Full Text] [Related]

  • 5. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM, Min HQ, Gao JS, Hong MH, Xiao XB, Zhang CQ, Liu XD, Zhang AL, Guo X.
    Ai Zheng; 2003 Mar 15; 22(3):302-6. PubMed ID: 12654192
    [Abstract] [Full Text] [Related]

  • 6. [Quantitative analysis of Epstein-Barr virus DNA in plasma and peripheral blood cells in patients with nasopharyngeal carcinoma].
    Zhang Y, Gao HY, Feng HX, Deng L, Huang MY, Hu B, Cheng G, Wu QL, Cui NJ, Shao JY.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 17; 84(12):982-6. PubMed ID: 15312530
    [Abstract] [Full Text] [Related]

  • 7. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS, Dekker PB, van Krieken JH, Baatenburg de Jong RJ, Kroes AC.
    J Clin Pathol; 2006 May 17; 59(5):537-41. PubMed ID: 16489178
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epstein-Barr virus DNA quantification and follow-up in Tunisian nasopharyngeal carcinoma patients.
    Hassen E, Farhat K, Gabbouj S, Bouaouina N, Abdelaziz H, Chouchane L.
    Biomarkers; 2011 May 17; 16(3):274-80. PubMed ID: 21506698
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term prognostic effects of plasma epstein-barr virus DNA by minor groove binder-probe real-time quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy.
    Lin JC, Wang WY, Liang WM, Chou HY, Jan JS, Jiang RS, Wang JY, Twu CW, Liang KL, Chao J, Shen WC.
    Int J Radiat Oncol Biol Phys; 2007 Aug 01; 68(5):1342-8. PubMed ID: 17449194
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW, Wang WY, Liang WM, Jan JS, Jiang RS, Chao J, Jin YT, Lin JC.
    Int J Radiat Oncol Biol Phys; 2007 Jan 01; 67(1):130-7. PubMed ID: 16979842
    [Abstract] [Full Text] [Related]

  • 14. Correlation of Epstein-Barr virus DNA in cell-free plasma, functional imaging and clinical course in locally advanced nasopharyngeal cancer: a pilot study.
    Mäkitie AA, Reis PP, Irish J, Zhang T, Chin SF, Chen X, Marriott C, Keller A, Perez-Ordonez B, Kamel-Reid S, Siu LL.
    Head Neck; 2004 Sep 01; 26(9):815-22. PubMed ID: 15350028
    [Abstract] [Full Text] [Related]

  • 15. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma.
    Leung SF, Zee B, Ma BB, Hui EP, Mo F, Lai M, Chan KC, Chan LY, Kwan WH, Lo YM, Chan AT.
    J Clin Oncol; 2006 Dec 01; 24(34):5414-8. PubMed ID: 17135642
    [Abstract] [Full Text] [Related]

  • 16. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma.
    Lo YM, Chan LY, Chan AT, Leung SF, Lo KW, Zhang J, Lee JC, Hjelm NM, Johnson PJ, Huang DP.
    Cancer Res; 1999 Nov 01; 59(21):5452-5. PubMed ID: 10554016
    [Abstract] [Full Text] [Related]

  • 17. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
    Li YH, Shao JY, Zhao MQ, Gao HY, Li LR, Guan ZZ, Zeng YX.
    Ai Zheng; 2003 Jun 01; 22(6):645-8. PubMed ID: 12948418
    [Abstract] [Full Text] [Related]

  • 18. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y.
    Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.